Literature DB >> 24294291

Considerations for patient selection for focal therapy.

John F Ward1, Louis L Pisters.   

Abstract

Focal therapy for prostate cancer is a nascent and emerging field. As such, the patient selection criteria for this new treatment paradigm are evolving in parallel to both the technology on which this approach depends and to our unfolding understanding of the natural history of prostate cancer. Until, and while, prospective trials of focal therapy are being reported, patient selection criteria will be flexible and very dependent on the therapeutic goals. We must carefully define the therapeutic intentions of focal therapy before engaging in the actual process of determining optimal patient selection. The therapeutic intent will define the most appropriate candidate for such therapy. Patient selection encompasses multiple complex issues including the type of prostate biopsy (12 core transrectal versus mapping transperineal) to the type of imaging (multiparametric magnetic resonance imaging or enhanced ultrasound) to the specific anatomical location of the disease within the prostate (apex, mid-prostate, base) and a comprehensive assessment of the patient's overall health and life expectancy. It is not as simple as saying a patient with a certain grade or a certain number of cores is or is not appropriate for focal therapy. There are many more considerations for a reasonable and thoughtful approach to this new treatment.

Entities:  

Keywords:  HIFU; MRI; ablation techniques; cryoablation; focal therapy; prostatic neoplasms; transrectal ultrasound

Year:  2013        PMID: 24294291      PMCID: PMC3825108          DOI: 10.1177/1756287213496127

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  38 in total

Review 1.  Focal therapy for prostate cancer: patient selection and evaluation.

Authors:  Stavros Gravas; Vassilios Tzortzis; Santiago Isorna Martinez de la Riva; Pilar Laguna; Jean de la Rosette
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion.

Authors:  Osamu Ukimura; Mihir M Desai; Suzanne Palmer; Samuel Valencerina; Mitchell Gross; Andre L Abreu; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2012-01-21       Impact factor: 7.450

Review 3.  Intraprostatic targeting.

Authors:  Osamu Ukimura; Kenneth Faber; Inderbir S Gill
Journal:  Curr Opin Urol       Date:  2012-03       Impact factor: 2.309

4.  Impotence following radical prostatectomy: insight into etiology and prevention.

Authors:  P C Walsh; P J Donker
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

5.  Clinical application of a 3D ultrasound-guided prostate biopsy system.

Authors:  Shyam Natarajan; Leonard S Marks; Daniel J A Margolis; Jiaoti Huang; Maria Luz Macairan; Patricia Lieu; Aaron Fenster
Journal:  Urol Oncol       Date:  2011 May-Jun       Impact factor: 3.498

6.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Authors:  Caroline M A Hoeks; Martijn G Schouten; Joyce G R Bomers; Stefan P Hoogendoorn; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Henk Vergunst; J P Michiel Sedelaar; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

7.  Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy.

Authors:  Nathan Lawrentschuk; Ants Toi; Gina A Lockwood; Andrew Evans; Antonio Finelli; Martin O'Malley; Myles Margolis; Sangeet Ghai; Neil E Fleshner
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

8.  Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.

Authors:  P C Walsh; H Lepor; J C Eggleston
Journal:  Prostate       Date:  1983       Impact factor: 4.104

Review 9.  MRI-ultrasound fusion for guidance of targeted prostate biopsy.

Authors:  Leonard Marks; Shelena Young; Shyam Natarajan
Journal:  Curr Opin Urol       Date:  2013-01       Impact factor: 2.309

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more
  1 in total

1.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.